Automated Insulin Delivery (AID) Systems
Over the past four decades, advances in blood glucose monitoring and insulin delivery have steadily reduced the burden of type 1 diabetes (T1D). Self-monitoring of blood glucose provided the foundation. Continuous glucose monitoring (CGM) transformed that foundation into a real-time picture. Now, hybrid closed-loop insulin pump therapy is bringing automation into the equation, making “artificial pancreas” systems a reality for everyday use.
What is Hybrid Closed-Loop Therapy?
Hybrid closed-loop systems combine three components:
- An insulin pump: Delivers rapid-acting insulin through a subcutaneous cannula.
- A CGM sensor: Continuously measures glucose levels in the interstitial fluid.
- A control algorithm: Uses CGM data to automatically adjust basal insulin delivery.
Unlike traditional pump therapy — where the user sets basal rates manually — hybrid closed-loop systems make small, automated adjustments every few minutes to keep glucose within target range. The “hybrid” part means the user still gives bolus doses for meals or large corrections, but much of the background insulin delivery is automated.
How Hybrid Closed-Loop Systems Work
- The CGM sends glucose readings to the pump every 1–5 minutes.
- The algorithm calculates whether to increase, decrease, or suspend insulin delivery.
- The pump adjusts basal insulin accordingly, aiming to maintain glucose within target range.
- Users still enter carbohydrate amounts and deliver meal boluses.
Benefits of Hybrid Closed-Loop Therapy
- Improved Time in Range: Clinical trials consistently show higher time-in-range and lower HbA1c compared with standard pump or multiple daily injections.
- Reduced Hypoglycaemia: Automated insulin suspension in response to falling glucose helps prevent lows, especially overnight.
- Less Decision Fatigue: Automation reduces the mental workload of frequent basal adjustments.
- Better Quality of Life: Many users report greater flexibility, better sleep, and reduced diabetes distress.
Limitations and Considerations
- User Input Still Required: Carbohydrate counting and bolus delivery remain essential.
- Cost and Access: Systems can be expensive; availability varies across regions.
- Learning Curve: Training is needed to understand settings, alarms, and troubleshooting.
- Technology Dependence: As with any device, there’s a risk of sensor or pump malfunction — back-up plans are necessary.
Who Can Benefit Most?
Hybrid closed-loop therapy can be valuable for:
- People with T1D struggling to reach glucose targets.
- Children and adolescents, especially those prone to hypoglycaemia.
- Adults with unpredictable schedules, shift work, or frequent travel.
- Anyone motivated to use technology to reduce daily management burden.
Future Directions: Toward Fully Closed-Loop Systems
Research is moving toward fully automated systems requiring little or no user input, sometimes called “fully closed loop” or “bionic pancreas” devices. These may include dual-hormone delivery (insulin plus glucagon or other agents) for even more stable glucose control. As algorithms and sensor accuracy improve, the gap between manual management and true automation will continue to narrow.
Hybrid closed-loop insulin pump therapy represents a major step forward in type 1 diabetes care. Building on the foundation of self-monitoring and continuous glucose monitoring, these systems automate much of the day-to-day insulin delivery, improving outcomes and easing the daily burden of diabetes management. While they are not yet a cure, hybrid closed-loop systems bring us closer than ever to the vision of an artificial pancreas — and a future where managing type 1 diabetes is simpler, safer, and more seamless.
Page updated: September 2025
